Taiwan Advance Bio-Pharmaceutical PEG Ratio

The latest PEG ratio for 4186.TWO is 13.22. That is below the Healthcare sector average of 27.75. Investors often review this figure alongside Taiwan Advance Bio-Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, 4186.TWO currently prints 13.22 for PEG ratio, while the sector average sits near 27.75. That is roughly 52.4% below the sector mean. Large gaps often invite a closer look at Taiwan Advance Bio-Pharmaceutical's growth, margins, and balance sheet.

A PEG ratio of 13.22 for Taiwan Advance Bio-Pharmaceutical is not 'good' or 'bad' on its own. Compare it with the peer average (27.75) and with 4186.TWO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting 4186.TWO's PEG ratio (13.22), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Taiwan Advance Bio-Pharmaceutical's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.